11-77192192-A-T
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_000260.4(MYO7A):c.4066A>T(p.Ser1356Cys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000719 in 1,613,934 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000260.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MYO7A | NM_000260.4 | c.4066A>T | p.Ser1356Cys | missense_variant | 31/49 | ENST00000409709.9 | NP_000251.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MYO7A | ENST00000409709.9 | c.4066A>T | p.Ser1356Cys | missense_variant | 31/49 | 1 | NM_000260.4 | ENSP00000386331 |
Frequencies
GnomAD3 genomes AF: 0.000401 AC: 61AN: 152260Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000642 AC: 16AN: 249208Hom.: 0 AF XY: 0.0000518 AC XY: 7AN XY: 135206
GnomAD4 exome AF: 0.0000376 AC: 55AN: 1461674Hom.: 0 Cov.: 32 AF XY: 0.0000358 AC XY: 26AN XY: 727116
GnomAD4 genome AF: 0.000401 AC: 61AN: 152260Hom.: 0 Cov.: 33 AF XY: 0.000417 AC XY: 31AN XY: 74390
ClinVar
Submissions by phenotype
not provided Uncertain:3Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Nov 01, 2016 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jan 12, 2023 | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge - |
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 30, 2024 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics | Jun 04, 2015 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jul 30, 2024 | Variant summary: MYO7A c.4066A>T (p.Ser1356Cys) results in a non-conservative amino acid change located in the FERM domain (IPR000299) of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 6.4e-05 in 249208 control chromosomes, predominantly at a frequency of 0.001 within the African or African-American subpopulation in the gnomAD database. This frequency is not significantly higher than estimated for a pathogenic variant in MYO7A causing Usher Syndrome (6.4e-05 vs 0.0061), allowing no conclusion about variant significance. c.4066A>T has been reported in the literature in the heterozygous state in an individual of African ancestry affected with profound congenital sensorineural hearing loss (Florentine_2022). This report does not provide unequivocal conclusions about association of the variant with Usher Syndrome or other MYO7A-related disorders. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publication have been ascertained in the context of this evaluation (PMID: 34515852). ClinVar contains an entry for this variant (Variation ID: 235215). Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 17, 2022 | The c.4066A>T (p.S1356C) alteration is located in exon 31 (coding exon 30) of the MYO7A gene. This alteration results from a A to T substitution at nucleotide position 4066, causing the serine (S) at amino acid position 1356 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Usher syndrome type 1B Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Natera, Inc. | Apr 16, 2020 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at